News»Psoriatic Arthritis Has a New FDA Approved DMARD - Apremilast
Psoriatic Arthritis Has a New FDA Approved DMARD - Apremilast
In March 2014 the FDA approved apremilast (Otezla) for use in psoriatic arthritis based on three large"Palace" trials involving 1493 psoriatic arthritis patients. This ACR Hotline reviews the drugs use, efficacy, and toxicity.
Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.
The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.
Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.
Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).